Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis

FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS

Dec 09, 2014, 07:00 ET from Eli Lilly and Company from ,Incyte Corporation

$countyNameToPathMap.put("sp